The need for a personalized approach for prostate cancer management
Open Access
- 9 May 2015
- journal article
- editorial
- Published by Springer Nature in BMC Medicine
- Vol. 13 (1) , 1-3
Abstract
The stratification of patients for treatment of prostate cancer is based on very general parameters like prostate-specific antigen, Gleason score, and TNM classification. We use these rough parameters for selection of active surveillance, active treatment, and even for the treatment selection in metastasized or castration-resistant prostate cancers. Up to now, we have not used individualized genetic classifiers for detailed sub-stratification, thus treating all patients as equal, and being only moderately successful. With the expected increase in systemic treatments, there is an apparent need for such classifiers. We will address these needs in this short commentary.Keywords
This publication has 8 references indexed in Scilit:
- A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate CancerEuropean Urology, 2015
- Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk StratificationEuropean Urology, 2015
- Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate CancerCancer Epidemiology, Biomarkers & Prevention, 2015
- Genomic Classifier Identifies Men With Adverse Pathology After Radical Prostatectomy Who Benefit From Adjuvant Radiation TherapyJournal of Clinical Oncology, 2015
- Multi-gene classifiers for prediction of recurrence in breast cancer patientsBreast Cancer, 2015
- Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy CohortJournal of Clinical Oncology, 2013
- Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer*Current Opinion in Urology, 2005
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per MilliliterNew England Journal of Medicine, 2004